Product Adoption and Expansion
-- More than 9,150 test results were delivered in the first quarter of
2008, compared to more than 5,450 test results delivered in the first
quarter of 2007. More than 55,000 test results have been delivered
since Oncotype DX became commercially available.
-- Based on additional clinical results presented at the December 2007 San
Antonio Breast Cancer Symposium, experienced an increase in use of
Oncotype DX for patients with node-positive breast cancer.
-- Enhanced clinical utility of Oncotype DX reports by providing
quantitative measurements of gene expression for estrogen and
Reimbursement for Oncotype DX
-- Gained coverage for over 21 million additional lives in the quarter for
access to Oncotype DX through contracts, policies and agreements,
bringing the total U.S. covered lives to approximately 80 percent.
-- Health Care Service Corporation (HCSC), which operates through Blue
Cross and Blue Shield divisions in Illinois, New Mexico, Oklahoma,
and Texas, established a positive coverage policy for Oncotype DX
covering approximately 10 million lives.
-- Blue Cross and Blue Shield of North Carolina established a policy
covering approximately 3.5 million lives.
-- Blue Cross and Blue Shield of Tennessee established a policy
covering approximately 3 million lives.
-- WellMark Blue Cross and Blue Shield, comprising plans in Iowa and
North Dakota, established a policy covering approximately 2 million
-- Blue Cross and Blue Shield plans in Kansas, Rhode Island and
Nebraska, as well as Health Alliance Plan of Michigan, established
policies covering a total of approximately 2.7 million lives.
|SOURCE Genomic Health, Inc.|
Copyright©2008 PR Newswire.
All rights reserved